Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
- 31 January 2009
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 55 (1) , 62-75
- https://doi.org/10.1016/j.eururo.2008.10.008
Abstract
No abstract availableKeywords
This publication has 107 references indexed in Scilit:
- Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyondUrologic Oncology: Seminars and Original Investigations, 2008
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008
- Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2007
- Androgen deprivation therapy for prostate cancer: new concepts and concernsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2007
- Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate CancerJournal of Clinical Oncology, 2007
- The rising prevalence of androgen deprivation among older American men since the advent of prostate‐specific antigen testing: a population‐based cohort studyBJU International, 2006
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castrationBJU International, 2006
- Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancerEuropean Journal Of Cancer, 2006